Business
Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer
Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11, The Lancet – one of the world’s most renowned academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. This study, led by MD Anderso
About this update from Ion Beam Applications Sa
[{"type":"image","alt":"IBA SA","displaySize":"","headline":null,"caption":"IBA SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":85,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/ab9cb8d53c1f491c2297f1d9274f5694"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z4qZvB1n65el3DgzVQJgKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTExMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ab9cb8d53c1f491c2297f1d9274f5694","width":85,"height":85}},"lazy":false},{"type":"horizontalRule"},{"type":"text","content":"Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11, The Lancet – one of the world’s most renowned academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. This study, led by MD Anderson Cancer Center, the world’s leading hospital for cancer care, is the first-ever randomized controlled trial (RCT) to provide the highest level of evidence demonstrating the benefits of proton therapy over conventional radiotherapy for this indication.","length":764,"tagName":"p"},{"type":"text","content":"Oropharyngeal cancer is a type of head and neck cancer that develops in the throat region, a highly sensitive area containing fragile, critical structures, making precisely targeted local treatments particularly relevant. It is a growing global health concern, with more than 100,0001 new cases diagnosed annually. Standard treatment, with the current state-of-the-art photon radiotherapy, intensity-modulated radiation therapy (IMRT) and chemotherapy, often results in major side effects, including significant weight loss, dependence on feeding tubes, dry mouth, and loss of taste.","length":583,"tagName":"p"},{"type":"text","content":"The trial involved over 20 institutions and enrolled 440 patients, representing the first-ever level 1 randomized phase 3 trial comparing Intensity-Modulated Proton Therapy (IMPT) with advanced photon therapy (IMRT).","length":216,"tagName":"p"},{"type":"text","content":"The MD Anderson study delivers Level 1 evidence with the following key findings:","length":80,"tagName":"p"},{"ty...